Novartis-AveXis: an $8.7bn gene repair
Novartis AG (SIX: NOVN) – market cap as of 20/04/2018: CHF204.12bn AveXis Inc (NASDAQ: AVXS) – market cap as of 20/04/2018: $7.62bn Introduction On April 9, Novartis submitted an offer to acquire all the shares of the American gene therapy group AveXis. The Swiss drugmaker offered an 88% premium adding Read more…